CBS Boston reports on a clinical trial that leverages kidneys infected with hepatitis C, potentially making many new organs available. “We’re giving [patients] the opportunity to have a transplant but we’re also treating them for a new infection they didn’t have. So that’s the trade-off,” commented Peter Reese, MD, MSCE.